Newsbenzinga
Johnson & Johnson Secures FDA Approval For First Rare Anemia Treatment
· Published
Article summary
Johnson & Johnson secured FDA approval for IMAAVY, the first targeted therapy to treat warm autoimmune hemolytic anemia in adults and youth.
An excerpt from the original article.
Comments —
Loading comments…